Stockholm, 12th January 2024 — Alex Therapeutics today announced a new Chair of the Board, with Hans-Peter Frank taking over the role from departing Board Chair, Warren Campbell.
We are thrilled with the appointment of Hans-Peter Frank as the new Alex Therapeutics Board Chair, and at the same time are very appreciative and thankful for all the hard work and guidance provided by the departing Chair, Warren Campbell.
As we continue to advance in our pursuit of being the leading partner to pharma for the development of evidence-based companion apps, we’re very happy to welcome Hans-Peter to the Alex Therapeutics Team.
“With over 25 years experience in the Life Sciences Industry, including roles in pharmaceutical, medical device, and digital health companies, Hans-Peter brings a wealth of industry-specific knowledge and experience to this role at Alex Therapeutics. Hans-Peter is an expert in the design, development and implementation of digital health solutions, including digital therapeutics, and will be instrumental in supporting the strategic and operational direction of the company going forward.” said John Drakenberg, CEO at Alex Therapeutics.
Alongside his new position at Alex Therapeutics, Hans-Peter holds a number of Executive Positions, where he advises as a subject matter and business development expert in Pharma, Medtech and BioTech. His past experience includes senior global commercial roles in digital health and business management at Novartis, Medtronic and Vifor Pharma, amongst others. Common across all his work, is his ability to advise on how to leverage digital technologies such as AI to deliver outstanding business results.
Earlier in his career, Hans-Peter also spent several years at the senior level of top consulting firms, including PwC, EY, Boston Consulting Group and Mckinsey. Hans-Peter also holds an MBA from Harvard Business School. When asked about his new role at Alex Therapeutics, he said:
“I am really excited to be joining the team at Alex Therapeutics as the new Chair of the Board. Alex is at the forefront of digital health transformation, and I have very strong belief that we are still in the early stages of a change in how health care systems and pharmaceutical companies partner with technology companies like Alex Therapeutics and the value we can bring to patients. Alex Therapeutics have a fantastic team and best-in-class technology platform, with AI-capabilities, which I believe is going to be integral to all digital health solutions going forward. I can’t wait to get started.”
Hans-Peter succeeds outgoing Board Chair Warren Campbell, who has held the position since 2018. Warren is an ex-McKinsey Partner, Advisor and Investor, who has extensive experience across a diverse range of industries, including healthcare and renewable energy. Warren joined Alex Therapeutics when the company was in its infancy, and has overseen its growth and expansion, advising on a range of strategic and operational issues, including multiple rounds of investment.
“I have truly enjoyed the 5 year journey I've had as the Board Chair at Alex Therapeutics. It has been an honor to contribute to the progress of the company, seeing it grow from an early stage start-up to the well-established, growing company it is today. I’ll take with me invaluable experiences, fond memories and personal connections for which I’ll be forever grateful. Together, we've been navigating at the intersection of technology innovation and healthcare, and I am confident that Alex Therapeutics will continue to thrive in this space. A big thanks to the other Board Members, as well as John and the entire team, for their support and I look forward to continuing to follow the success of the company going forward as a supportive investor.” said Warren Campbell.
Follow us on LinkedIn to stay updated on the latest news and developments at Alex Therapeutics.
